Shares of RadioShack Corp. (RSH) are trading up more than 37% in Friday’s pre-market session after the electronics retailer struck a deal with a consortium of lenders led by New York-based hedge fund Standard General LP to refinance about $590M of loans to re-stock ahead of the crucial holiday season, Bloomberg reported, citing a person familiar with the matter.
The refinancing is in the form of a new $535 million asset-backed revolving credit line from GE Capital, the lending unit of General Electric (GE), Bloomberg said.
RSH shares recently gained $0.40 to $1.39. In the past 52 weeks, shares of Fort Worth, Texas-based retailer have traded between a low of $0.55 and a high of $3.88. Shares are down 70.80% year-over-year and 61.92% year-to-date.
Shares of Tekmira Pharmaceuticals Corp (TKMR) rose about 8 percent in early pre-market trading on the Nasdaq following reports of NBC News freelancer in Liberia being diagnosed with Ebola. The case comes after a traveler from Liberia was found this week to have Ebola in the U.S., making him the first patient diagnosed in the country. The patient is being treated at a hospital in Dallas, TX.
Tekmira Pharmaceuticals, which is working to develop an Ebola vaccine, has received FDA authorization to use its TKM-EBOLA treatement under an expanded access protocol in individuals that are already infected with Ebola virus.
Tekmira Pharmaceuticals, currently valued at $552.43M, has a median Wall Street price target of $27.53 with a high target of $28.44. Approximately 14,489,120 shares changed hands during Thursday’s trading session compared to the stock’s average daily volume of 4,206,250.
In the past 52 weeks, shares of Canadian drugmaker have traded between a low of $7.17 and a high of $31.48. TKMR currently prints a one year return of about 246.06% and a year-to-date return of around 219.57%.
Tekmira has a Relative Strength Index (RSI) and MACD indicator of 66.21 and +1.83, respectively.
Another stock moving in reaction to the Ebola news is Biocryst Pharmaceuticals (BCRX). Ticker is up 6.72% changing hands at $12.15.
BioCryst Pharmaceuticals, Inc., currently valued at $816.94M, has a median Wall Street price target of $18.00 with a high target of $24.00. In the past 52 weeks, shares of the clinical-stage biopharmaceutical company have traded between a low of $4.55 and a high of $14.62 with the 50-day MA and 200-day MA located at $12.13 and $10.97 levels, respectively. Shares of BCRX have a Relative Strength Index (RSI) of 49.21 and a MACD indicator of and -0.36.
BCRX currently prints a one year return of about 51.66% and a year-to-date return of around 49.87%.
Salix Pharmaceuticals Ltd. (SLXP) recently traded at $158.50, up 4.90% on news the company is in discussions to be acquired by Actavis Plc (ACT), after it failed to reach a deal with Botox maker Allegran (AGN).
In other Salix Pharma news; the company was upgraded this morning to ‘Neutral’ from ‘Underperform’ with a $155 price target at Credit Suisse (CS).
On valuation-measures, shares of Salix Pharmaceuticals Ltd. have a trailing-12 and forward P/E of 167.32 and 21.58, respectively. P/E to growth ratio is 1.27, while t-12 profit margin is 4.67%. EPS registers at $0.90. The company has a market cap of $9.62B and a median Wall Street price target of $177.00 with a high target of $195.00.
On trading-measure, SLXP has a beta of 0.93 and a short float of 14.68%. In the past 52 weeks, shares of Raleigh, North Carolina-based firm have traded between a low of $67.40 and a high of $172.98 with the 50-day MA and 200-day MA located at $154.86 and $126.64 levels, respectively.
SLXP currently prints a one year return of about 112.80% and a year-to-date return of around 67.99%.
Mylan, Inc. (MYL) shares surged nearly 6 percent on pre-market trading Friday after the company announced that it expects Q3 adjusted diluted EPS to be in the range of $1.12 to $1.16/share, an increase from the previously communicated third quarter range of $0.90 to $0.95/share. Increased Q3 guidance range includes $0.14/share as a result of an agreement with Strides Arcolab Limited.
Mylan, Inc. recently traded up $2.85 to $49.35. Approximately 15,776,623 changed hands during Thursday’s trading session, compared to the stock’s average daily volume of 4,899,820 shares.
On valuation-measures, shares of Mylan, Inc. have a trailing-12 and forward P/E of 31.65 and 11.86, respectively. T-12 profit margin is 8.14%, while EPS registers at $1.47. The company has a market cap of $17.39B and a median Wall Street price target of $60.00 with a high target of $70.00.
On trading-measure, MYL has a beta of 0.77 and a short float of 7.80%. In the past 52 weeks, shares of Canonsburg, Pennsylvania-based company have traded between a low of $36.97 and a high of $57.52 with the 50-day MA and 200-day MA located at $47.20 and $49.00 levels, respectively.
MYL currently prints a one year return of about 17.75% and a year-to-date return of around 7.14%.